Stephen Bloch Sells 82,736 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDAGet Free Report) Director Stephen Bloch sold 82,736 shares of Liquidia stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $64.97, for a total value of $5,375,357.92. Following the completion of the transaction, the director directly owned 1,787,306 shares in the company, valued at $116,121,270.82. This trade represents a 4.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Liquidia Price Performance

Shares of Liquidia stock opened at $64.01 on Wednesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The business’s 50 day simple moving average is $47.90 and its two-hundred day simple moving average is $40.11. The stock has a market capitalization of $5.69 billion, a P/E ratio of 457.25 and a beta of 0.58. Liquidia Corporation has a one year low of $11.85 and a one year high of $66.78.

Liquidia (NASDAQ:LQDAGet Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Analysts forecast that Liquidia Corporation will post 2.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on LQDA shares. Needham & Company LLC boosted their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Lifesci Capital raised Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Jefferies Financial Group reissued a “buy” rating and set a $60.00 target price on shares of Liquidia in a research note on Monday, May 11th. Oppenheimer set a $75.00 target price on Liquidia in a research note on Friday. Finally, BTIG Research boosted their target price on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $55.63.

View Our Latest Research Report on Liquidia

Institutional Investors Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC grew its stake in Liquidia by 1.1% in the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after purchasing an additional 90,400 shares during the period. Vanguard Group Inc. grew its stake in Liquidia by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after purchasing an additional 52,671 shares during the period. Opaleye Management Inc. grew its stake in Liquidia by 9.5% in the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after purchasing an additional 215,000 shares during the period. Bank of America Corp DE grew its stake in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after purchasing an additional 360,372 shares during the period. Finally, Caprock Group LLC grew its stake in Liquidia by 9.3% in the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after purchasing an additional 151,832 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

About Liquidia

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

See Also

Insider Buying and Selling by Quarter for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.